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Epigenetic changes in gene expression play a role in
the development of diabetic complications, including
nephropathy. Histone deacetylases (HDACs) are a
group of enzymes that exert epigenetic effects by al-
tering the acetylation status of histone and nonhis-
tone proteins. In the current study, we investigated
the action of the clinically available HDAC inhibitor
vorinostat in a mouse model of diabetic nephropathy,
with the following aims: to define its effect on the
progression of renal injury and to explore its mech-
anism of action by focusing on its role in regulating
the expression of endothelial nitric oxide synthase
(eNOS). Control and streptozotocin-diabetic wild-type
and eNOS–/– mice were treated with vorinostat by
daily oral dosing for 18 weeks. Without affecting ei-
ther blood glucose concentration or blood pressure,
vorinostat decreased albuminuria, mesangial collagen
IV deposition, and oxidative-nitrosative stress in
streptozotocin–wild-type mice. These attenuating ef-
fects were associated with a >50% reduction in eNOS
expression in mouse kidneys and in cultured human
umbilical vein endothelial cells. Vorinostat treatment
had no effect on albuminuria, glomerular collagen IV
concentration, or mesangiolysis in diabetic mice genet-
ically deficient in eNOS. These observations illustrate
the therapeutic efficacy of long-term HDAC inhibition
in diabetic nephropathy and emphasize the importance
of the interplay between eNOS activity and oxidativestress in mediating these effects. (Am J Pathol 2011, 178:
2205–2214; DOI: 10.1016/j.ajpath.2011.01.044)
The ability to regulate gene expression is a fundamental
attribute of all cells, providing them with the versatility
needed to adapt to an ever-changing microenvironment.
Although some alterations in gene expression are short-
lived, others are far more enduring, providing the transcrip-
tional machinery with access to large regions of DNA for
extended periods. Such modifications are frequently semi-
permanent, involving chemical changes to DNA that in-
clude the (de)methylation of cytosine nucleotides and the
(de)acetylation of nucleosome histones. Given the persis-
tent and heritable nature of their effects, these “epigenetic”
changes have provided mechanistic insights into embry-
onic development, neoplastic transformation, and, most re-
cently, glycemic memory, affording a plausible explanation
for the persistent reduction in diabetic complications long
after an earlier phase of intensive glycemic control.1,2
In addition to expanding our understanding of pathoge-
netic processes, epigenetic phenomena provide new mo-
lecular targets that are potentially amenable to therapeutic
manipulation. Although the pharmacological modification
of the epigenome is still in its infancy, several clinical
trials using drugs that target it are in progress, with one
agent, the histone deacetylase inhibitor (HDACi), vorinos-
tat (suberoylanilide hydroxamic acid), gaining regulatory
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AJP May 2011, Vol. 178, No. 5approval for the treatment of advanced cutaneous T-cell
lymphoma in 2006. Although investigation into the poten-
tial beneficial effects of inhibitors of HDACs has primarily
focused on neoplastic and neurodegenerative disorders,
their ability to modulate the expression of genes involved
in the physiological and pathophysiological conditions of
the cardiovascular system suggests their broader appli-
cability.
One protein known to be regulated by histone modifi-
cation is endothelial nitric oxide synthase (eNOS),3
viewed as playing a pivotal, but complex, role in the
pathogenesis of diabetic nephropathy. Although eNOS
deficiency, through genetic deletion, promotes albumin-
uria in the diabetic setting,4–7 the enzyme may also con-
tribute to the development of tissue injury through its role
in the generation of reactive oxygen species (ROS),8,9 a
process commonly referred to as eNOS uncoupling.
ROS, generated through increased mitochondrial glyco-
lytic flux10 and impaired antioxidant systems11 in the set-
ting of hyperglycemia, may react with eNOS-derived NO
to form peroxynitrite. Oxidization of the eNOS cofactor
tetrahydrobiopterin by peroxynitrite may subsequently
promote the further generation of superoxide in prefer-
ence to NO.12,13 Accordingly, in the hyperglycemic mi-
lieu, even “normal” levels of eNOS may contribute to
oxidative-nitrosative stress.
In this primarily translational study, we sought to ex-
plore the effects of HDACi administration in a murine
model of diabetic nephropathy, focusing on the potential
benefits that might be afforded by this strategy and, more
specifically, on the relationship between HDAC inhibition,
eNOS activity, and ROS formation.
Materials and Methods
In Vivo Experiments
Male C57BL/6 and eNOS–/– mice (n  7 to 11 per group)
were obtained from Jackson Laboratories (Bar Harbor,
ME) at the age of 7 weeks. Diabetes mellitus was induced
according to a low-dose streptozotocin (STZ) protocol,14
as previously described.7 Animals were randomized to
receive a daily i.p. injection of STZ (50 mg/kg) for 5
consecutive days in 0.1 mol/L sodium citrate buffer (pH
4.5) or citrate buffer alone. Two weeks after the initial STZ
injection, diabetes was confirmed by measurement of a
fed blood glucose concentration (Accu-check Advan-
tage; Roche, Mississauga, ON); and only animals with a
blood glucose concentration 16 mmol/L were consid-
ered diabetic. Mice were subsequently randomized to
receive either vorinostat (50 mg/kg)15,16 (Exclusive
Chemistry Ltd, Obninsk, Russia) or vehicle [0.5% meth-
ylcellulose (w/v) and 0.1% Tween 80 (v/v)] by once-daily
oral gavage and were observed for 18 weeks.
Systolic blood pressure was measured in anesthetized
mice (2% isoflurane) using a noninvasive tail blood pres-
sure system (CODA; Kent Scientific, Torrington, CT).
HbA1c was measured using A1cNow (Bayer, Sunny-
vale, CA). The serum creatinine concentration was deter-
mined by the Bartel modification of Jaffe’s alkaline picricacid method. Albuminuria was determined after housing
mice in metabolic cages for 24 hours after 2 to 3 hours’
habituation. Animals continued to have free access to tap
water and a standard laboratory diet during this period.
After 24 hours in metabolic cages, an aliquot of urine was
collected from the 24-hour urine sample and stored at
80°C for subsequent analysis. Urine albumin excretion
was determined with a mouse albumin enzyme-linked im-
munosorbent assay (AssayMax; Assaypro, St Charles,
MO). Urine creatinine concentration was determined with a kit
(Creatinine Companion; Exocell, Philadelphia, PA). Urinary
8-hydroxydeoxyguanosine (8-OHdG) concentration was de-
termined with a kit (Bioxytech 8-OHdG-EIA; Oxis Health
Products Inc., Foster City, CA).
All experimental procedures adhered to the guidelines
of the Canadian Council on Animal Care and were ap-
proved by St Michael’s Hospital Animal Care Committee.
Tissue Collection
Animals were anesthetized with 2% inhaled isoflurane
before cervical dislocation. The right renal artery was
clamped and the kidney was removed, decapsulated,
sliced transversely, and immersed in 10% neutral-buff-
ered formalin overnight. Tissues were routinely pro-
cessed, embedded in paraffin, and sectioned. The left
kidney was removed, decapsulated, and either snap fro-
zen in liquid nitrogen and stored at 80°C for later mo-
lecular biological analysis or cryoembedded in optical
cutting temperature compound, flash frozen over dry ice
for 15 minutes, and stored at 80°C for subsequent
immunofluorescence staining.
Immunohistochemistry
IHC for acetyl-histone H3 (1:60; Cell Signaling, Danvers,
MA), collagen IV (1:800; Millipore, Billerica, MA), and
nitrotyrosine (1:50; Abcam, Cambridge, MA) was per-
formed as previously described.11,17,18 Incubation with
PBS instead of primary antiserum served as the nega-
tive control. After incubation with the appropriate
horseradish peroxidase– conjugated secondary anti-
bodies, sections were labeled with the liquid di-
aminobenzidine and substrate chromogen system
(DakoCytomation, Glostrup, Denmark) before counter-
staining in Mayer’s hematoxylin. For determination of
histone H3 acetylation in mouse kidneys, the number of
positively (brown) staining tubular nuclei was deter-
mined in three randomly selected cortical fields (400
magnification) from each mouse kidney section. For es-
timation of glomerular collagen IV deposition, slides were
scanned with a system (Aperio ScanScope; Aperio Tech-
nologies Inc., Vista, CA) and analyzed using ImageS-
cope (Aperio Technologies Inc.), with the proportional
glomerular area positive for collagen IV immunostaining
determined in 15 randomly selected glomerular profiles
from each kidney section. Data are expressed as the fold
change relative to that of vehicle-treated nondiabetic an-
imals.
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Glomerular volume was calculated on 4-m PAS-stained
kidney sections using the following formula:
Glomerular Volume  ( ⁄ k)(GA)3⁄2
where  1.38 pertains to the sphere and k 1.10 is the
distribution coefficient.19
Mesangiolysis
The presence of mesangiolysis was determined in 50
glomeruli from eNOS–/– mice after staining kidney sec-
tions with silver methenamine.
Electron Microscopy
Small pieces of cortical tissue (1 mm3) were fixed in 2%
glutaraldehyde, postfixed in osmium tetroxide, dehy-
drated in acetone, and embedded in epoxy resin. Ultra-
thin sections were taken through three randomly selected
glomeruli from four mice per group, stained with uranyl
acetate and lead citrate, and examined using a transmis-
sion electron microscope (Philips CM100; EM Research
Services, Newcastle University, Newcastle upon Tyne,
UK). Electron micrographs of the whole glomerular profile
were taken at 1100 magnification. Mesangial volume
fraction was estimated by superimposing a grid of coarse
and fine points (ratio, 1:8) on each image. Fine points
landing on mesangial tissue were counted and ex-
pressed as a fraction of coarse points landing on the
glomerular tuft, the boundary being defined by a mini-
mal–string polygon.20
Confocal Microscopy
Frozen kidney sections, 10-m thick, were cut on a cry-
ostat (Leica CM1900) and fixed in 4% paraformaldehyde/
PBS (pH 7.4) for 5 minutes before incubation with 0.1%
Triton X-100, 1% BSA, and normal donkey serum diluted
1:50 in PBS (blocking serum) for 45 minutes. Sections
were then exposed to rabbit polyclonal anti-eNOS anti-
body (1:75; Abcam) in blocking serum at 4°C overnight.
Slides were washed and incubated with donkey anti-
rabbit IgG (Alexa Fluor 488), diluted 1:100 in PBS for 2
hours (Invitrogen, Carlsbad, CA). Confocal microscopy
was performed on a confocal microscope (Leica TCS SL)
Table 1. Functional Characteristics of Control and STZ-Diabetic
Treatment B.wt. (g)
Systolic BP
(mm Hg)
C57BL/6  vehicle 30.1  0.5 121  4 4
C57BL/6  vorinostat 28.2  0.6 121  3 4
STZ-C57BL/6  vehicle 22.0  1.3* 115  4 12
STZ-C57BL/6  vorinostat 20.5  1.1 109  3 12
Data are given as mean SEM.
BP, blood pressure.
*P  0.001 versus C57BL/6  vehicle.
†P  0.05 versus C57BL/6  vehicle.
‡P  0.05 versus STZ-C57BL/6  vehicle.using a 20 objective (PlanApo; numerical aperture,
0.7).
In Vitro Experiments
Human umbilical vein endothelial cells were cultured and
characterized as previously described, with experiments
performed in passage 3 to 4 cells.21 Cells were incu-
bated with either vorinostat at the concentrations de-
scribed or vehicle (dimethyl sulfoxide) for 24 hours.
RNA and Protein Isolation
RNA was isolated from cultured cell lysates using reagent
(TRIzol; Life Technologies, Grand Island, NY). For deter-
mination of gene expression in mice kidneys, tissue
stored at80°C was homogenized (Polytron, Kinematica
Gmbh, Littau, Switzerland). Total RNA (4 g) was treated
with RQ1 DNase (1 U/L) (Promega, Madison, WI) to
remove genomic DNA. RNA was reverse transcribed with
a kit (High-Capacity cDNA Reverse Transcription Kit; Ap-
plied Biosystems, Foster City, CA), according to the man-
ufacturer’s instructions. Protein was isolated from cul-
tured cell extracts or mouse kidney homogenates (n  3)
after washing in PBS with cell lysis buffer (Cell Signaling)
containing 1 mmol/L phenylmethylsulfonyl fluoride. The
protein concentration was determined with an assay (Bio-
Rad DC Protein Assay; Bio-Rad, Hercules, CA). SDS–
polyacrylamide gel electrophoresis was performed after
loading gels with 50 g of protein.
Immunoblotting
Immunoblotting on nitrocellulose membranes was per-
formed with primary antibodies in the following concen-
trations: acetyl-histone H3 (Lys9), 1:1000 (Cell Signaling);
total histone H3, 1:1000 (Cell Signaling); nitrotyrosine,
1:1000 (Abcam); -actin, 1:5000 (Abcam); and eNOS,
1:5000 (BD Transduction Laboratories, Lexington, KY).
After incubation with the appropriate horseradish peroxi-
dase–conjugated secondary antibodies, proteins were
detected by the electrochemiluminescence system (Am-
ersham, Buckinghamsire, UK). Nitrotyrosine was deter-
mined by densitometry of a prominent approximately 210-
kDa nitrated protein band, as previously described.22
Densitometry was performed using software (ImageJ, ver-
sion 1.39) from the National Institutes of Health (http://rsb.
info.nih.gov/ij, last accessed March 9, 2011).
6 Mice Treated with Vehicle or Vorinostat for 18 Weeks
c
Kidney wt. (g)
Kidney wt.,
b.wt. (%)
Albumin/creatinine
ratio (g/mg)
.1 0.166 0.005 0.55  0.01 51.6 / 1.1
.1 0.151 0.003 0.54  0.01 57.2 / 1.2
.1* 0.216  0.013* 0.98  0.02* 128.5 / 1.2†
.3 0.185  0.005‡ 0.91  0.03 48.1 / 1.3‡C57BL/
HbA1
(%)
.9  0
.7  0
.8  0
.6  0
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Measurement of eNOS gene expression was performed
using SYBR Green on a system (ABI Prism 7900HT Fast
PCR System; Applied Biosystems). Sequence-specific
primers were designed to span exon-exon boundaries us-
ing computer software (Primer Express, v1.5; Applied Bio-
systems). Primers were obtained from ACGT Corp (Toronto,
ON). Primer sequences were as follows: mouse RPL13A,
5=-GCTCTCAAGGTTGTTCGGCTGA-3= (forward) and 5=-
AGATCTGCTTCTTCTTCCGATA-3= (reverse)23; mouse
eNOS, 5=-GGCATCACCAGGAAGAACACC-3= (forward)
and 5=-TCACTCGCTTCGCCATCAC-3= (reverse); human
eNOS, 5=-GGGTCCTGTGTATGGATGAGTATG-3= (for-
ward) and 5=-GGCCGGACATCTCCATCAG-3= (reverse);
Figure 1. Effect of vorinostat on histone hyperacetylation in vitro and in
vivo. A: Immunoblotting for total and acetylated histone H3 in lysates from
human umbilical vein endothelial cells exposed to dimethyl sulfoxide or 10
mol/L vorinostat for 24 hours. B–E: IHC for acetylated histone H3 with
C57BL/6  vehicle (B), C57BL/6  vorinostat (C), STZ-C57BL/6  vehicle
(D), and STZ-C57BL/6  vorinostat (E). F: Quantitation of acetylated histone
H3–positive nuclei. *P  0.01 versus C57BL/6  vehicle; **P  0.01 versus
STZ-C57BL/6  vehicle.and human RPL32, 5=-CAACATTGGTTATGGAAGCA-ACA-3= (forward) and 5=-TGACGTTGTGGACCAGGA-
ACT-3= (reverse).24 Experiments were performed in trip-
licate, and data analysis was performed using the
comparative CT method (Applied Biosystems).
Statistics
Data are presented as mean  SEM, unless otherwise
indicated. Statistical significance was determined by
one-way analysis of variance with a Newman-Keuls post
hoc comparison. All statistical analyses were performed
using software (GraphPad Prism version 5.00 for Mac;
GraphPad Software, San Diego, CA). P  0.05 was con-
sidered statistically significant.
Results
Vorinostat Attenuates Renal Injury in
Diabetic Mice
To determine the effect of long-term HDAC inhibition in
diabetic nephropathy, control and STZ-diabetic C57BL/6
mice were treated with vehicle or the HDACi vorinostat by
daily oral gavage for 18 weeks (Table 1). In both cultured
human umbilical vein endothelial cells and in the kidneys
of control and diabetic mice, treatment with vorinostat
resulted in an expected increase in acetylation of histone
H3 (Figure 1). After 18 weeks, diabetic mice had a re-
duced b.wt. and an increased kidney size compared with
nondiabetic animals (Table 1). Vorinostat treatment was
well tolerated in both control and diabetic wild-type mice,
with no effect on survival and a nonsignificant reduction
in b.wt. (Table 1). At study end, albuminuria, considered
as either the 24-hour albumin excretion rate or the albu-
min/creatinine ratio, was increased approximately 2.5-
fold in STZ-C57BL/6 mice compared with controls (Table
1 and Figure 2). Without affecting either blood glucose or
blood pressure, vorinostat treatment significantly de-
creased albuminuria after both 12 and 18 weeks of dia-
betes (Table 1 and Figure 2). Similarly, kidney size, glo-
merular volume, and mesangial matrix accumulation
(determined by either immunostaining for collagen IV or
Figure 2. Urine albumin excretion in control and diabetic mice treated with
vehicle or vorinostat. *P 0.001 versus C57BL/6 vehicle; **P 0.01 versus
STZ-C57BL/6  vehicle; ***P  0.05 versus STZ-C57BL/6  vehicle.
HDAC Inhibition and eNOS in Diabetes 2209
AJP May 2011, Vol. 178, No. 5calculating the mesangial fractional volume by transmis-
sion electron microscopy) were each increased in STZ-
C57BL/6 mice relative to controls and were reduced with
vorinostat (Table 1 and Figure 3).
Oxidative-Nitrosative Stress Is Increased in
Diabetes and Reduced with Vorinostat
The effect of vorinostat on oxidative-nitrosative stress was
evaluated using both Western blot analysis and IHC for
nitrotyrosine, reflecting peroxynitrite activity, and by de-termining the urinary excretion of 8-OHdG, a marker of
oxidative DNA damage. As an indicator of cellular ni-
trosylation, we quantitated nitrotyrosine in an approxi-
mately 210-kDa heavily nitrated protein band, as previ-
ously reported,22 identifying an increase in nitrotyrosine
in the kidneys from diabetic mice that was reduced with
vorinostat treatment (Figure 4A). By IHC, nitrotyrosine
was increased in both tubular and glomerular endothelial
compartments and reduced in vorinostat-treated diabetic
mice (Figure 4, B–F). Similarly, vorinostat treatment also
reduced the 24-hour urinary excretion of 8-OHdG that
Figure 3. Renal structure in control and
STZ-diabetic C57BL/6 mice treated with ve-
hicle or vorinostat for 18 weeks. A: Glomer-
ular volume. B–E: Glomerular collagen IV
immunostaining with C57BL/6  vehicle
(B), C57BL/6  vorinostat (C), STZ-C57BL/
6  vehicle (D), and STZ-C57BL/6  vori-
nostat (E). Original magnification, 400. F:
Quantitation of glomerular collagen IV rep-
resented as fold change relative to C57BL/
6  vehicle. G–J: Mesangial fractional vol-
ume (Vv Mes/glom) of C57BL/6  vehicle
(G), C57BL/6  vorinostat (H), STZ-
C57BL/6 vehicle (I), STZ-C57BL/6 vori-
nostat (J). K: Vv Mes/glom. *P  0.001 ver-
sus C57BL/6  vehicle; **P  0.05 versus
STZ-C57BL/6  vehicle.
Figure 4. Oxidative-nitrosative stress in control
and STZ-diabetic C57BL/6 mice treated with ve-
hicle or vorinostat for 18 weeks. A and B: Im-
munoblotting for nitrotyrosine in kidney homoge-
nates revealed the presence of an approximately
210-kDa protein band, the nitrosylation of which
was increased with diabetes mellitus and reduced
with vorinostat. C–F: Immunostaining for nitro-
tyrosine with C57BL/6  vehicle (C), C57BL/6 
vorinostat (D), STZ-C57BL/6  vehicle (E), and
STZ-C57BL/6  vorinostat (F). G: Urinary
8-OHdG excretion in control and diabetic mice
treated with vehicle or vorinostat for 18 weeks.
*P  0.05 versus all other groups; **P  0.001
versus C57BL/6 vehicle; ***P 0.05 versus STZ-
C57BL/6  vehicle. AU indicates arbitrary unit.
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mice (Figure 4G).
Vorinostat Decreases eNOS Expression in the
Kidneys of Diabetic Mice and in Cultured
Endothelial Cells
After 18 weeks, the magnitude of renal expression of both
eNOS mRNA and eNOS protein was equivalent in vehi-
cle-treated diabetic and nondiabetic wild-type mice, with
the distribution of the protein being restricted to the en-
dothelium of glomeruli and arterioles (Figure 5, A–F).
Real-time PCR of kidney homogenates revealed that
eNOS mRNA was reduced by approximately 50% in the
kidneys of both control and diabetic mice treated with
vorinostat (Figure 5F). In cultured human umbilical vein
endothelial cells, vorinostat dose dependently reduced
eNOS protein and mRNA, such that with 10 mol/L vori-
nostat, eNOS mRNA was reduced by 80% (Figure 5, G
and H).
Mice Genetically Deficient in eNOS Are
Resistant to the Attenuating Effects of
Vorinostat
Finally, to confirm the pivotal role of eNOS repression in
mediating the nephroprotective effects of vorinostat, we
sought to explore the response to HDAC inhibition in the
setting of absolute eNOS deficiency by treating control
and STZ-diabetic eNOS–/– mice with either vehicle or
vorinostat by daily oral gavage for 18 weeks. Compared
with either diabetic wild-type animals or nondiabetic
eNOS–/– mice, heavy albuminuria was observed in vehi-
cle-treated STZ-eNOS–/– animals (Figure 6, A and B),
without a significant change in 8-OHdG excretion. Uri-nary 8-OHdG concentrations were as follows: eNOS–/–,
22.7  5.1 ng/24 hours; and STZ-eNOS–/–, 30.3  3.9
ng/24 hours (P  0.28). Although vorinostat treatment
was associated with a reduction in kidney size (Table 2)
in STZ-eNOS–/– mice, it had no effect on either albumin-
uria (Figure 6, A and B) or glomerular collagen IV depo-
sition (Figure 6, C–G). Mesangiolysis was a prominent
feature of the glomerular pathological characteristics
seen in STZ-eNOS–/– mice, occurring in approximately
10% of glomeruli. As observed with other parameters of
renal structure and function, there was no difference in
the proportion of glomeruli displaying evidence of me-
sangiolysis between vehicle- and vorinostat-treated STZ-
eNOS–/– mice (Figure 6, H–L).
Discussion
During recent years, HDAC inhibitors have emerged as a
class of agents with therapeutic potential for the treat-
ment of complex chronic diseases, including diabetes. In
the current study, we explored the efficacy of long-term
HDAC inhibition using the orally bioavailable broad-spec-
trum HDACi, vorinostat. Treatment of diabetic mice with
vorinostat resulted in a persistent attenuation of oxidative
stress, albuminuria, and mesangial matrix accumulation.
Given the wide range of target genes that are regulated
by acetylation of histone proteins at their promoter re-
gions, HDAC inhibition is likely to affect multiple injurious
pathways in diabetes. However, the findings of the cur-
rent study indicate a pivotal role for eNOS down-regula-
tion in mediating the effects of HDAC inhibition, as evi-
denced by the reduction in kidney and endothelial cell
eNOS mRNA after vorinostat administration and the ab-
sence of an effect in the setting of eNOS gene deletion.
These findings, combined with the known role that eNOS
Figure 5. eNOS protein and mRNA in mouse kid-
neys and cultured human umbilical vein endothe-
lial cells (HUVECs). A–D: Immunofluorescence for
eNOS protein with C57BL/6  vehicle (A),
C57BL/6  vorinostat (B), STZ-C57BL/6  vehicle
(C), and STZ-C57BL/6  vorinostat (D). E: Immu-
noblotting kidney homogenates for eNOS protein.
F: Real-time PCR for eNOS in kidney homogenates
of control and STZ-diabetic C57BL/6 mice treated
with vehicle or vorinostat. G and H: Effect of
HDAC inhibition with vorinostat on eNOS expres-
sion in cultured HUVECs treated with dimethyl
sulfoxide or vorinostat for 24 hours on eNOS pro-
tein (G) and eNOS mRNA (H). Data are given for
the mean of three experiments. *P  0.001 versus
C57BL/6  vehicle; **P  0.05 versus STZ-
C57BL/6  vehicle; ***P  0.001 versus control;
****P  0.01 versus 5 mol/L vorinostat. AU indi-
cates arbitrary unit.uncoupling plays in diabetes-associated ROS genera-
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in chronic kidney disease beyond previously described
antifibrotic effects.
Originally developed for their antiproliferative proper-
ties in transformed cells,25,26 inhibitors of HDACs have
more recently been applied in a spectrum of experimen-
tal models of nonneoplastic disease.27 The first evidence
for an antialbuminuric action of broad-spectrum HDAC
Table 2. Functional Characteristics of eNOS–/– Mice Treated with
Treatment B.wt. (g)
Systolic BP
(mm Hg)
S
eNOS–/–  vehicle 27.3  0.6 133  3
eNOS–/–  vorinostat 26.4  0.6 135  3
STZ-eNOS–/–  vehicle 20.4  0.5* 110  4*
STZ-eNOS–/–  vorinostat 18.8  1.3 110  3
Data are given as mean  SEM.
BP, blood pressure.
*P  0.001 versus eNOS–/–  vehicle.
†P  0.01 versus eNOS–/–  vehicle.
‡ –/–P  0.01 versus STZ-eNOS  vehicle.
§P  0.05 versus STZ-eNOS–/–  vehicle.inhibition was in a murine model of lupus nephritis.28
Unfortunately, the agent used in the initial study28 and in
several subsequent studies,29–31 trichostatin A, is limited
by its low oral bioavailability and relatively short half-
life.32 Accordingly, we explored the properties of the
orally bioavailable and clinically applicable HDACi, vori-
nostat. Similarly, although the studies with trichostatin A
in kidney disease have primarily focused on the agent’s
Figure 6. Renal structure and function in con-
trol and diabetic eNOS–/– mice treated with ve-
hicle or vorinostat for 18 weeks. A: Urine albu-
min excretion. B: Urine albumin/creatinine ratio.
C–F: Glomerular collagen IV immunostaining
for eNOS–/– vehicle (C), eNOS–/– vorinostat
(D), STZ-eNOS–/–  vehicle (E), and STZ-
eNOS–/–  vorinostat (F). Original magnifica-
tion, 400. G: Quantitation of glomerular colla-
gen IV represented as fold change relative to
eNOS–/–  vehicle. H–K: Representative photo-
micrographs of silver methenamine–stained kid-
ney sections from eNOS–/–  vehicle (H),
eNOS–/–  vorinostat (I), STZ-eNOS–/–  vehi-
cle (J), and STZ-eNOS–/–  vorinostat (K), dem-
onstrating mesangiolytic glomeruli in both vehi-
cle- and vorinostat-treated STZ-eNOS–/– mice.
Original magnification, 400. L: Percentage of
mesangiolytic glomeruli. *P  0.01 versus
eNOS–/– vehicle; **P 0.05 versus eNOS–/–
vehicle. AU indicates arbitrary unit.
le or Vorinostat for 18 Weeks
creatinine
(mg/dL) HbA1c (%) Kidney wt. (g)
Kidney wt.,
b.wt. (%)
 0.08 4.9  0.1 0.138  0.004 0.50  0.01
 0.11 4.7  0.1 0.131  0.003 0.50  0.01
 0.51† 12.5  0.4* 0.186  0.006* 0.91  0.02*
 0.30 12.2  0.4 0.152  0.012‡ 0.83  0.04§Vehic
erum
10–1
0.91
1.31
2.50
2.27
2212 Advani et al
AJP May 2011, Vol. 178, No. 5actions in antagonizing transforming growth factor- and
its prosclerotic effects,29–31 we set out to examine alter-
native mechanisms of action, using a diabetic mouse
model that is characterized by the development of albu-
minuria and modest mesangial expansion but that is rel-
atively resistant to late-stage fibrotic disease.33 Consis-
tent with observations in other mouse strains,33 we
observed a reduction in systolic blood pressure in both
wild-type and eNOS–/– mice in the context of STZ-
induced diabetes. Without affecting either blood pres-
sure or blood glucose concentration, vorinostat de-
creased albuminuria, glomerular hypertrophy, and
glomerular collagen IV deposition, the chief collage-
nous component of mesangial matrix that is increased
in diabetes,34 suggesting the potential for this class of
agent to exert a beneficial effect in diabetic nephrop-
athy as an adjunct to antihyperglycemic and antihyper-
tensive strategies.
In neoplasia, the ability to promote ROS accumulation
is a major mechanism underlying the cytotoxic effects of
HDAC inhibitors.35,36 However, one of the most remark-
able properties of these agents is their cytotoxic selec-
tivity for transformed cells.37 In fact, low doses of HDAC
inhibitors have been repeatedly cytoprotective in neuro-
degenerative diseases,38,39 with specific inhibition of
HDAC6 attenuating oxidative stress–induced neuronal in-
jury.40 Conversely, hydrogen peroxide increases HDAC
activity in cultured tubular epithelial cells,41 indicating a
bidirectional relationship between the oxidation-reduc-
tion and histone acetylation status of the cell. Our obser-
vations, and studies in other models of kidney disease,
illustrate a persistent benefit of HDAC inhibition de-
spite the apparent potential for this class of agent to
promote oxidative stress. One mechanism for the anti-
oxidant effect of vorinostat in diabetes is the reduction
in eNOS mRNA and protein levels observed in vitro and
in vivo. Although this decrease in eNOS expression did
not appear to affect renal function in normoglycemic
animals, it was associated with a reduction in oxida-
tive-nitrosative stress in diabetic mice, consistent with
the known actions of eNOS in mediating the formation
of superoxide and peroxynitrite in the setting of re-
duced substrate bioavailability and high ambient glu-
cose concentrations.8,9
The transcriptional regulation of eNOS is an archetypal
example of a cell-specific histone code. In endothelial
cells, the eNOS promoter is highly enriched with acety-
lated histones.42 In previous experiments, HDAC inhibi-
tion with trichostatin A decreased eNOS mRNA while
paradoxically increasing the activity of its promoter, sug-
gesting the induction of an eNOS mRNA-destabilizing
factor.3 This factor has subsequently been identified as
the antisense mRNA, sONE.43 Because vorinostat non-
selectively inhibits the actions of class I (HDACs 1 to 3
and 8) and class II (HDACs 4 to 7, 9, and 10) HDAC
enzymes and potentially increases the lysine acetylation
status of more than 1700 nonhistone proteins,44 we did
not seek to precisely define which HDACs are implicated
in the pathogenesis of diabetic nephropathy. Instead, we
took a translational approach to determine the long-term
efficacy of a clinically available HDACi.As with many factors implicated in the pathogenesis of
diabetic complications, the role that eNOS plays in ne-
phropathy is dependent on its relative expression levels,
with detrimental effects reported in the setting of both
enhanced and reduced eNOS activity. Although absolute
eNOS deficiency, through genetic knockout, markedly
augments albuminuria in diabetic mice,4–7 increased NO
generation has been implicated in the pathogenesis of
glomerular hypertrophy, hyperfiltration, and microalbu-
minuria in early diabetes.45,46 As has been previously
described,4–7 we observed heavy albuminuria in diabetic
eNOS–/– mice in the absence of an increase in oxidative
injury,7 illustrating the critical role that eNOS plays in both
the regulation of macromolecular flow across the filtration
barrier and the formation of oxygen radicals in the pres-
ence of hyperglycemia. In contrast to the pathological
effects of genetic eNOS deletion, incomplete down-reg-
ulation of eNOS, by HDAC inhibition, was renoprotective
in diabetes by decreasing oxidative-nitrosative stress.
The failure to demonstrate an antialbuminuric effect of
vorinostat in STZ-eNOS–/– mice highlights the limitations
of knockout models for the study of novel therapies, in
which the deleted gene is implicated in the pathogenetic
process. Many knockout mouse models are derived on
the C57BL/6 genetic background strain that, in contrast
to some other mouse strains, is relatively nephropathy
resistant.47 Accordingly, both a strength and a weakness
of the current study is that the renal injury observed in
STZ-C57BL/6 mice was relatively mild. For example, we
did not identify a significant worsening in tubulointerstitial
fibrosis in these animals (data not shown), relative to
normoglycemic mice, enabling the elucidation of a novel
renoprotective mechanism for HDAC inhibition (eNOS
down-regulation) beyond previously identified antifibrotic
effects.31 Although the current study entailed a daily ga-
vage treatment for 18 weeks, it remains to be determined
whether even longer-term treatment with vorinostat would
attenuate later-stage renal fibrosis in diabetes.
In summary, long-term treatment with vorinostat im-
proved albuminuria and mesangial matrix accumulation
in diabetic mice through an eNOS-dependent mecha-
nism. These findings provide further support to a growing
body of evidence attesting to the potential utility of HDAC
inhibitors for the treatment of cardiorenal diseases.27
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